JP4596651B2 - （ｅ）−スチリルスルホン抗癌剤 - Google Patents

（ｅ）−スチリルスルホン抗癌剤 Download PDF

Info

Publication number
JP4596651B2
JP4596651B2 JP2000609059A JP2000609059A JP4596651B2 JP 4596651 B2 JP4596651 B2 JP 4596651B2 JP 2000609059 A JP2000609059 A JP 2000609059A JP 2000609059 A JP2000609059 A JP 2000609059A JP 4596651 B2 JP4596651 B2 JP 4596651B2
Authority
JP
Japan
Prior art keywords
chloro
hydrogen
fluoro
fluorostyryl
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000609059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541102A5 (enExample
JP2002541102A (ja
Inventor
レディー，イー，プレムクマー
レディー，エム，ブイ，ラマナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University
Original Assignee
Temple University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University filed Critical Temple University
Publication of JP2002541102A publication Critical patent/JP2002541102A/ja
Publication of JP2002541102A5 publication Critical patent/JP2002541102A5/ja
Application granted granted Critical
Publication of JP4596651B2 publication Critical patent/JP4596651B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000609059A 1999-04-02 2000-03-31 （ｅ）−スチリルスルホン抗癌剤 Expired - Fee Related JP4596651B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12768399P 1999-04-02 1999-04-02
US14397599P 1999-07-15 1999-07-15
US60/127,683 1999-07-15
US60/143,975 1999-07-15
PCT/US2000/008565 WO2000059495A1 (en) 1999-04-02 2000-03-31 (e)-styryl sulfone anticancer agents

Publications (3)

Publication Number Publication Date
JP2002541102A JP2002541102A (ja) 2002-12-03
JP2002541102A5 JP2002541102A5 (enExample) 2007-05-24
JP4596651B2 true JP4596651B2 (ja) 2010-12-08

Family

ID=26825868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000609059A Expired - Fee Related JP4596651B2 (ja) 1999-04-02 2000-03-31 （ｅ）−スチリルスルホン抗癌剤

Country Status (7)

Country Link
EP (1) EP1173160B1 (enExample)
JP (1) JP4596651B2 (enExample)
AT (1) ATE298234T1 (enExample)
AU (1) AU774738B2 (enExample)
CA (1) CA2366750C (enExample)
DE (1) DE60020954T2 (enExample)
WO (1) WO2000059495A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388343A1 (en) * 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
WO2002067913A1 (en) 2001-02-27 2002-09-06 Temple University-Of The Commonwealth System Of Higher Education (z)-styrylbenzylsulfones and pharmaceutical uses thereof
US6667346B2 (en) 2001-02-28 2003-12-23 Temple University - Of The Commonwealth System Of Higher Education Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
AU2004289281C1 (en) * 2003-11-14 2011-12-08 Onconova Therapeutics, Inc. Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders
AU2005222947B2 (en) * 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
US8664272B2 (en) * 2006-08-30 2014-03-04 Temple University—Of the Commonwealth System of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3463774A (en) * 1963-03-18 1969-08-26 Hoffmann La Roche Novel 4,1-benzothiazepin-2-(1h)-ones and 4,1-benzothiazepines
JPH0641054A (ja) * 1992-07-27 1994-02-15 Mitsubishi Petrochem Co Ltd スチリルスルホン誘導体、それを有効成分とする殺菌剤およびその製造方法
TR199801495T2 (xx) * 1995-06-07 1998-09-21 Eli Lilly And Company Vinil s�lfoksitler ve sentezlenmeleri i�in bir i�lem.
ATE284386T1 (de) * 1997-10-03 2004-12-15 Univ Temple Styrolsulfone als antikrebsmittel
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
WO2000059494A1 (en) * 1999-04-02 2000-10-12 Temple University- Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
IL149064A0 (en) * 1999-10-12 2002-11-10 Univ Temple Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Also Published As

Publication number Publication date
AU774738B2 (en) 2004-07-08
EP1173160B1 (en) 2005-06-22
CA2366750A1 (en) 2000-10-12
ATE298234T1 (de) 2005-07-15
EP1173160A4 (en) 2003-02-19
DE60020954T2 (de) 2006-05-11
CA2366750C (en) 2010-06-01
AU4185300A (en) 2000-10-23
WO2000059495A1 (en) 2000-10-12
JP2002541102A (ja) 2002-12-03
EP1173160A1 (en) 2002-01-23
DE60020954D1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
US6787667B2 (en) (E)-styryl sulfone anticancer agents
US6486210B2 (en) Substituted styryl benzylsulfones for treating proliferative disorders
JP4468593B2 (ja) Ｚ−スチリルスルホン抗癌剤
AU2001251615A1 (en) Substituted styryl benzylsulfones for treating proliferative disorders
AU2001251614C1 (en) Alpha,beta-unsaturated sulfones for treating proliferative disorders
EP1173160B1 (en) (e)-styryl sulfone anticancer agents
AU2001251614A1 (en) Alpha,beta-unsaturated sulfones for treating proliferative disorders
CA2424884C (en) Substituted (e)-styryl benzylsulfones for treating proliferative disorders
JP2002541101A (ja) スチリルスルホン抗癌剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100921

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131001

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees